Loading
A phase 2 trial of RVU120 (SEL120) in myelodysplastic syndromes / neoplasms, run by GCP-Service International West GmbH, active and no longer recruiting.
RVU120 for Treatment of Anemia in Patients With Lower-risk Myelodysplastic Neoplasms is a phase 2 interventional study registered as NCT06243458 by GCP-Service International West GmbH, with 41 participants enrolled, started 2024-09-10 and due to reach its primary completion in 2026-05. Interventions recorded: RVU120 (SEL120).
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Ryvu Therapeutics and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.